Pliva Opens New Oral Solid Forms Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pliva Opens New Oral Solid Forms Facility



Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's production capacities for tablets and capsules in addition to increasing exports as the majority of these products are intended for international markets. The $100 million investment also covers the transfer of the existing pilot plant for tablets to the new facility and an increase of production capacities for sterile forms.

This new facility will raise Pliva's and Teva's annual capacity by 2 billion tablets or more than 25%. Medicinal products manufactured in the new production facility are intended for EU and US markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.

Source: Pliva

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here